Aradigm Corporation And APT Pharmaceutical LLC Initiate Phase 2 Clinical Program Of Novel Treatment For Asthma

Published: Mar 23, 2006

Aradigm Corporation (NASDAQ: ARDM) and APT Pharmaceuticals Inc., a privately held biotechnology company, today announced the initiation of their Phase 2 clinical trial investigating aerosolized hydroxychloroquine (HCQ) as an anti-inflammatory treatment for asthma. This clinical program will investigate the safety and efficacy of a novel aerosolized formulation of HCQ using Aradigm's AERx® pulmonary delivery system.

Back to news